Re: Diet for Metabolic Syndrome and fatty liver

[Guest guest]

Post-mortem and liver biopsy studies have shown that more than 80% of people with HIV have "non-alcoholic fatty liver." Fatty liver deregulates lipid metabolism and eventually leads to liver fibrosis and cirrhosis. The "Diet for Metabolic Syndrome" you posted lists Betaine as a treatment.

I previously posted a study by the Mayo Clinic, reproduced below, which showed 6 grams per day of Betaine, a metabolite of Choline and a methyl-donor, was very effective in reducing fat deposits in the liver after one year of treatment. There was a reduction in liver enzymes after only one month of usage.

I take Betaine in eight 750 mg tablets divided into two doses. It smells fresh and if you suck on it, slightly acidic and citrus. I have found it to be very effective.

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.

Abdelmalek MF, Angulo P, nsen RA, Sylvestre PB, Lindor KD.

Am J Gastroenterol. 2001 Sep;96(9):2711-7.

American Journal of Gastroenterolgy. 2001 Sep;96(9):2534-6 PMID: 11569673.

Divisions of Gastroenterology and Hepatology and Surgical Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

OBJECTIVES: No effective therapy currently exists for patients with nonalcoholic steatohepatitis (NASH). Betaine, a naturally occurring metabolite of choline, has been shown to raise S-adenosylmethionine (SAM) levels that may in turn play a role in decreasing hepatic steatosis. Our aim was to determine the safety and effects of betaine on liver biochemistries and histological markers of disease activity in patients with NASH.

METHODS: Ten adult patients with NASH were enrolled. Patients received betaine anhydrous for oral solution (Cystadane) in two divided doses daily for 12 months. Seven out of 10 patients completed 1 yr of treatment with betaine.

RESULTS: A significant improvement in serum levels of aspartate aminotransferase (p = 0.02) and ALAT (p = 0.007) occurred during treatment. Aminotransferases normalized in three of seven patients, decreased by >50% in three of seven patients, and remained unchanged in one patient when compared to baseline values. A marked improvement in serum levels of aminotransferases (ALT -39%; AST -38%) also occurred during treatment in those patients who did not complete 1 yr of treatment. Similarly, a marked improvement in the degree of steatosis, necroinflammatory grade, and stage of fibrosis was noted at 1 yr of treatment with betaine. Transitory GI adverse events that did not require any dose reduction or discontinuation of betaine occurred in four patients. CONCLUSIONS: Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH. This novel agent deserves further evaluation in a randomized, placebo-controlled trial.

>> _http://www.commonvoice.com/article.asp?colid=4270_ > (http://www.commonvoice.com/article.asp?colid=4270) > Diet for Metabolic Syndrome> Regina Wilshire> March 1, 2006> > Metabolic Syndrome > While doing a search last night for some information about one of the > complications of Metabolic Syndrome, I stumbled upon an interesting review in the > World Journal of Gastroenterology - _Non-alcoholic fatty liver disease and the > metabolic syndrome: Effects of weightloss and a review of popular diets. > Are low carbohydrate diets the answer?_ > (http://www.wjgnet.com/1007-9327/12/345.asp) > Researchers at the University of Connecticut Health Center, in Farmington, > Connecticut, reviewed the role of the metabolic syndrome, especially insulin > resistance and obesity in the development of non-alcoholic fatty liver > disease (NAFLD), to investigate the effect of weight loss on NAFLD and, finally, to > evaluate popular diets and compare them with regard to their effects on the > metabolic syndrome and NAFLD. > The above article is fairly long, but the researchers take things step by > step and review the degeneative processes that occur in metabolic syndrome. > They then look at the various therapies that have been evaluated, "Therapies > that have been evaluated include lifestyle changes such as diet and exercise, > antioxidants like vitamin E and betaine, cytoprotective agents such as > ursodeoxycholic acid, lipid-lowering agents, anti-diabetics, weight-loss agents like > orlistat and iron reduction therapy, i.e. phlebotomy. The management of > associated conditions, such as diabetes, obesity and hyperlipidemia, is > especially important, given their association with more advanced liver disease." > The most common of these therapies is weight loss since it, by itself, often > leads to improvements in insulin sensitivity, cholesterol, blood pressure and > glycemic control - all problems associated with metabolic syndrome. Their > concern, however is that "Improvement in liver biochemistry and > ultrasonographic appearance is a consistent finding with moderate weight reduction. > However, serum aminotransferases are unreliable markers for follow-up, and do not > provide accurate data on prognosis. Worsening of fibrosis can occur even as > the levels of transaminases decline. A few studies have evaluated and shown > histologic improvement." > After a review of traditional weight loss recommendation studies, they move > to "popular diets." > The effects of many popular diets on fatty liver are not known. However, > metabolic improvements related to dietary weight reduction may favorably > influence NASH. If dietary intervention can positively affect insulin resistance and > other features of the metabolic syndrome, it would be important to know > which particular diet is most beneficial. > One of the most startling statements in the review "A diet high in > carbohydrates results in an increase in blood glucose, insulin and triglycerides, all > of which are risk factors for the development of NAFLD." > This was stated after a favorable look at studies that used traditional > dietary therapies! > Most researchers are well aware of the dangers of low-fat carbohydrate rich > diets and I have to applaud these researchers for stating it here simply - > the literature is rich with data that clearly shows low-fat diets do not result > in significant improvements, but few will state it - it there in their data, > but they simply omit any questions or concerns with "unfavorable" outcomes > from low-fat diets. > These researchers continue, "Carbohydrate restriction leads to ketosis > resulting not only in weight loss, but also a decrease in blood glucose, insulin > and triglyceride levels. Studies have shown these diets to be effective in > short-term weight loss. Early weight loss is a result of diuresis associated > with ketone and urea nitrogen excretion. However, over time, weight loss is a > result of loss of body fat. Proponents believe that these diets have a high > satiety level, which make them easier to adhere to. This is very important, as > dietary adherence is one of the main challenges faced by dieters. Questions > with regard to their nutritional adequacy and long-term effects have been > raised. In the short-term, these diets have been found to be safe. " > When reviewing studies that compared a low-fat diet to a low-carb diet, it > was found that "Effects on biochemical markers associated with the metabolic > syndrome appear to be more favorable with low-carbohydrate diets. In general, > these diets show greater improvements in insulin sensitivity, triglyceride and > high-density cholesterol levels. It is possible that for patients with the > metabolic syndrome, a low-carbohydrate diet may be more advantageous. This, in > turn, may positively affect NAFLD." > In their conclusions - "Traditionally, a low-fat diet has been recommended, > but recent studies, show greater short-term weight loss and greater > improvement in markers of the metabolic syndrome without significant adverse effects > with low-carbohydrate diets. This raises the question of whether > low-carbohydrate diets should be recommended as part of a weight loss strategy for our > patients. At this point, questions regarding the nutritional adequacy and > long-term safety remain. While studies have evaluated the effect of these diets on > weight loss, cardiovascular and metabolic marker studies are needed to > evaluate the effect of these diets specifically on NAFLD."> > Regards,> > > Vergel> powerusa dot org> > > "The great tragedy of life is not that people set their sights too high and > fail to achieve their goals but they set their sights too low and do."> Michelangelo>

[Guest guest]

Post-mortem and liver biopsy studies have shown that more than 80% of people with HIV have "non-alcoholic fatty liver." Fatty liver deregulates lipid metabolism and eventually leads to liver fibrosis and cirrhosis. The "Diet for Metabolic Syndrome" you posted lists Betaine as a treatment.

I previously posted a study by the Mayo Clinic, reproduced below, which showed 6 grams per day of Betaine, a metabolite of Choline and a methyl-donor, was very effective in reducing fat deposits in the liver after one year of treatment. There was a reduction in liver enzymes after only one month of usage.

I take Betaine in eight 750 mg tablets divided into two doses. It smells fresh and if you suck on it, slightly acidic and citrus. I have found it to be very effective.

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.

Abdelmalek MF, Angulo P, nsen RA, Sylvestre PB, Lindor KD.

Am J Gastroenterol. 2001 Sep;96(9):2711-7.

American Journal of Gastroenterolgy. 2001 Sep;96(9):2534-6 PMID: 11569673.

Divisions of Gastroenterology and Hepatology and Surgical Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

OBJECTIVES: No effective therapy currently exists for patients with nonalcoholic steatohepatitis (NASH). Betaine, a naturally occurring metabolite of choline, has been shown to raise S-adenosylmethionine (SAM) levels that may in turn play a role in decreasing hepatic steatosis. Our aim was to determine the safety and effects of betaine on liver biochemistries and histological markers of disease activity in patients with NASH.

METHODS: Ten adult patients with NASH were enrolled. Patients received betaine anhydrous for oral solution (Cystadane) in two divided doses daily for 12 months. Seven out of 10 patients completed 1 yr of treatment with betaine.

RESULTS: A significant improvement in serum levels of aspartate aminotransferase (p = 0.02) and ALAT (p = 0.007) occurred during treatment. Aminotransferases normalized in three of seven patients, decreased by >50% in three of seven patients, and remained unchanged in one patient when compared to baseline values. A marked improvement in serum levels of aminotransferases (ALT -39%; AST -38%) also occurred during treatment in those patients who did not complete 1 yr of treatment. Similarly, a marked improvement in the degree of steatosis, necroinflammatory grade, and stage of fibrosis was noted at 1 yr of treatment with betaine. Transitory GI adverse events that did not require any dose reduction or discontinuation of betaine occurred in four patients. CONCLUSIONS: Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH. This novel agent deserves further evaluation in a randomized, placebo-controlled trial.

>> _http://www.commonvoice.com/article.asp?colid=4270_ > (http://www.commonvoice.com/article.asp?colid=4270) > Diet for Metabolic Syndrome> Regina Wilshire> March 1, 2006> > Metabolic Syndrome > While doing a search last night for some information about one of the > complications of Metabolic Syndrome, I stumbled upon an interesting review in the > World Journal of Gastroenterology - _Non-alcoholic fatty liver disease and the > metabolic syndrome: Effects of weightloss and a review of popular diets. > Are low carbohydrate diets the answer?_ > (http://www.wjgnet.com/1007-9327/12/345.asp) > Researchers at the University of Connecticut Health Center, in Farmington, > Connecticut, reviewed the role of the metabolic syndrome, especially insulin > resistance and obesity in the development of non-alcoholic fatty liver > disease (NAFLD), to investigate the effect of weight loss on NAFLD and, finally, to > evaluate popular diets and compare them with regard to their effects on the > metabolic syndrome and NAFLD. > The above article is fairly long, but the researchers take things step by > step and review the degeneative processes that occur in metabolic syndrome. > They then look at the various therapies that have been evaluated, "Therapies > that have been evaluated include lifestyle changes such as diet and exercise, > antioxidants like vitamin E and betaine, cytoprotective agents such as > ursodeoxycholic acid, lipid-lowering agents, anti-diabetics, weight-loss agents like > orlistat and iron reduction therapy, i.e. phlebotomy. The management of > associated conditions, such as diabetes, obesity and hyperlipidemia, is > especially important, given their association with more advanced liver disease." > The most common of these therapies is weight loss since it, by itself, often > leads to improvements in insulin sensitivity, cholesterol, blood pressure and > glycemic control - all problems associated with metabolic syndrome. Their > concern, however is that "Improvement in liver biochemistry and > ultrasonographic appearance is a consistent finding with moderate weight reduction. > However, serum aminotransferases are unreliable markers for follow-up, and do not > provide accurate data on prognosis. Worsening of fibrosis can occur even as > the levels of transaminases decline. A few studies have evaluated and shown > histologic improvement." > After a review of traditional weight loss recommendation studies, they move > to "popular diets." > The effects of many popular diets on fatty liver are not known. However, > metabolic improvements related to dietary weight reduction may favorably > influence NASH. If dietary intervention can positively affect insulin resistance and > other features of the metabolic syndrome, it would be important to know > which particular diet is most beneficial. > One of the most startling statements in the review "A diet high in > carbohydrates results in an increase in blood glucose, insulin and triglycerides, all > of which are risk factors for the development of NAFLD." > This was stated after a favorable look at studies that used traditional > dietary therapies! > Most researchers are well aware of the dangers of low-fat carbohydrate rich > diets and I have to applaud these researchers for stating it here simply - > the literature is rich with data that clearly shows low-fat diets do not result > in significant improvements, but few will state it - it there in their data, > but they simply omit any questions or concerns with "unfavorable" outcomes > from low-fat diets. > These researchers continue, "Carbohydrate restriction leads to ketosis > resulting not only in weight loss, but also a decrease in blood glucose, insulin > and triglyceride levels. Studies have shown these diets to be effective in > short-term weight loss. Early weight loss is a result of diuresis associated > with ketone and urea nitrogen excretion. However, over time, weight loss is a > result of loss of body fat. Proponents believe that these diets have a high > satiety level, which make them easier to adhere to. This is very important, as > dietary adherence is one of the main challenges faced by dieters. Questions > with regard to their nutritional adequacy and long-term effects have been > raised. In the short-term, these diets have been found to be safe. " > When reviewing studies that compared a low-fat diet to a low-carb diet, it > was found that "Effects on biochemical markers associated with the metabolic > syndrome appear to be more favorable with low-carbohydrate diets. In general, > these diets show greater improvements in insulin sensitivity, triglyceride and > high-density cholesterol levels. It is possible that for patients with the > metabolic syndrome, a low-carbohydrate diet may be more advantageous. This, in > turn, may positively affect NAFLD." > In their conclusions - "Traditionally, a low-fat diet has been recommended, > but recent studies, show greater short-term weight loss and greater > improvement in markers of the metabolic syndrome without significant adverse effects > with low-carbohydrate diets. This raises the question of whether > low-carbohydrate diets should be recommended as part of a weight loss strategy for our > patients. At this point, questions regarding the nutritional adequacy and > long-term safety remain. While studies have evaluated the effect of these diets on > weight loss, cardiovascular and metabolic marker studies are needed to > evaluate the effect of these diets specifically on NAFLD."> > Regards,> > > Vergel> powerusa dot org> > > "The great tragedy of life is not that people set their sights too high and > fail to achieve their goals but they set their sights too low and do."> Michelangelo>

[Guest guest]

Post-mortem and liver biopsy studies have shown that more than 80% of people with HIV have "non-alcoholic fatty liver." Fatty liver deregulates lipid metabolism and eventually leads to liver fibrosis and cirrhosis. The "Diet for Metabolic Syndrome" you posted lists Betaine as a treatment.

I previously posted a study by the Mayo Clinic, reproduced below, which showed 6 grams per day of Betaine, a metabolite of Choline and a methyl-donor, was very effective in reducing fat deposits in the liver after one year of treatment. There was a reduction in liver enzymes after only one month of usage.

I take Betaine in eight 750 mg tablets divided into two doses. It smells fresh and if you suck on it, slightly acidic and citrus. I have found it to be very effective.

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.

Abdelmalek MF, Angulo P, nsen RA, Sylvestre PB, Lindor KD.

Am J Gastroenterol. 2001 Sep;96(9):2711-7.

American Journal of Gastroenterolgy. 2001 Sep;96(9):2534-6 PMID: 11569673.

Divisions of Gastroenterology and Hepatology and Surgical Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.

OBJECTIVES: No effective therapy currently exists for patients with nonalcoholic steatohepatitis (NASH). Betaine, a naturally occurring metabolite of choline, has been shown to raise S-adenosylmethionine (SAM) levels that may in turn play a role in decreasing hepatic steatosis. Our aim was to determine the safety and effects of betaine on liver biochemistries and histological markers of disease activity in patients with NASH.

METHODS: Ten adult patients with NASH were enrolled. Patients received betaine anhydrous for oral solution (Cystadane) in two divided doses daily for 12 months. Seven out of 10 patients completed 1 yr of treatment with betaine.

RESULTS: A significant improvement in serum levels of aspartate aminotransferase (p = 0.02) and ALAT (p = 0.007) occurred during treatment. Aminotransferases normalized in three of seven patients, decreased by >50% in three of seven patients, and remained unchanged in one patient when compared to baseline values. A marked improvement in serum levels of aminotransferases (ALT -39%; AST -38%) also occurred during treatment in those patients who did not complete 1 yr of treatment. Similarly, a marked improvement in the degree of steatosis, necroinflammatory grade, and stage of fibrosis was noted at 1 yr of treatment with betaine. Transitory GI adverse events that did not require any dose reduction or discontinuation of betaine occurred in four patients. CONCLUSIONS: Betaine is a safe and well tolerated drug that leads to a significant biochemical and histological improvement in patients with NASH. This novel agent deserves further evaluation in a randomized, placebo-controlled trial.

>> _http://www.commonvoice.com/article.asp?colid=4270_ > (http://www.commonvoice.com/article.asp?colid=4270) > Diet for Metabolic Syndrome> Regina Wilshire> March 1, 2006> > Metabolic Syndrome > While doing a search last night for some information about one of the > complications of Metabolic Syndrome, I stumbled upon an interesting review in the > World Journal of Gastroenterology - _Non-alcoholic fatty liver disease and the > metabolic syndrome: Effects of weightloss and a review of popular diets. > Are low carbohydrate diets the answer?_ > (http://www.wjgnet.com/1007-9327/12/345.asp) > Researchers at the University of Connecticut Health Center, in Farmington, > Connecticut, reviewed the role of the metabolic syndrome, especially insulin > resistance and obesity in the development of non-alcoholic fatty liver > disease (NAFLD), to investigate the effect of weight loss on NAFLD and, finally, to > evaluate popular diets and compare them with regard to their effects on the > metabolic syndrome and NAFLD. > The above article is fairly long, but the researchers take things step by > step and review the degeneative processes that occur in metabolic syndrome. > They then look at the various therapies that have been evaluated, "Therapies > that have been evaluated include lifestyle changes such as diet and exercise, > antioxidants like vitamin E and betaine, cytoprotective agents such as > ursodeoxycholic acid, lipid-lowering agents, anti-diabetics, weight-loss agents like > orlistat and iron reduction therapy, i.e. phlebotomy. The management of > associated conditions, such as diabetes, obesity and hyperlipidemia, is > especially important, given their association with more advanced liver disease." > The most common of these therapies is weight loss since it, by itself, often > leads to improvements in insulin sensitivity, cholesterol, blood pressure and > glycemic control - all problems associated with metabolic syndrome. Their > concern, however is that "Improvement in liver biochemistry and > ultrasonographic appearance is a consistent finding with moderate weight reduction. > However, serum aminotransferases are unreliable markers for follow-up, and do not > provide accurate data on prognosis. Worsening of fibrosis can occur even as > the levels of transaminases decline. A few studies have evaluated and shown > histologic improvement." > After a review of traditional weight loss recommendation studies, they move > to "popular diets." > The effects of many popular diets on fatty liver are not known. However, > metabolic improvements related to dietary weight reduction may favorably > influence NASH. If dietary intervention can positively affect insulin resistance and > other features of the metabolic syndrome, it would be important to know > which particular diet is most beneficial. > One of the most startling statements in the review "A diet high in > carbohydrates results in an increase in blood glucose, insulin and triglycerides, all > of which are risk factors for the development of NAFLD." > This was stated after a favorable look at studies that used traditional > dietary therapies! > Most researchers are well aware of the dangers of low-fat carbohydrate rich > diets and I have to applaud these researchers for stating it here simply - > the literature is rich with data that clearly shows low-fat diets do not result > in significant improvements, but few will state it - it there in their data, > but they simply omit any questions or concerns with "unfavorable" outcomes > from low-fat diets. > These researchers continue, "Carbohydrate restriction leads to ketosis > resulting not only in weight loss, but also a decrease in blood glucose, insulin > and triglyceride levels. Studies have shown these diets to be effective in > short-term weight loss. Early weight loss is a result of diuresis associated > with ketone and urea nitrogen excretion. However, over time, weight loss is a > result of loss of body fat. Proponents believe that these diets have a high > satiety level, which make them easier to adhere to. This is very important, as > dietary adherence is one of the main challenges faced by dieters. Questions > with regard to their nutritional adequacy and long-term effects have been > raised. In the short-term, these diets have been found to be safe. " > When reviewing studies that compared a low-fat diet to a low-carb diet, it > was found that "Effects on biochemical markers associated with the metabolic > syndrome appear to be more favorable with low-carbohydrate diets. In general, > these diets show greater improvements in insulin sensitivity, triglyceride and > high-density cholesterol levels. It is possible that for patients with the > metabolic syndrome, a low-carbohydrate diet may be more advantageous. This, in > turn, may positively affect NAFLD." > In their conclusions - "Traditionally, a low-fat diet has been recommended, > but recent studies, show greater short-term weight loss and greater > improvement in markers of the metabolic syndrome without significant adverse effects > with low-carbohydrate diets. This raises the question of whether > low-carbohydrate diets should be recommended as part of a weight loss strategy for our > patients. At this point, questions regarding the nutritional adequacy and > long-term safety remain. While studies have evaluated the effect of these diets on > weight loss, cardiovascular and metabolic marker studies are needed to > evaluate the effect of these diets specifically on NAFLD."> > Regards,> > > Vergel> powerusa dot org> > > "The great tragedy of life is not that people set their sights too high and > fail to achieve their goals but they set their sights too low and do."> Michelangelo>

[Guest guest]

When taking 6 grams of Betaine it is important to note that Betaine, also known as "Anhydrous Betaine" or "Trimethylglycine" is not interchangeable with Betaine HCl.

Betaine HCl is used to increase stomach acid. You cannot safely take 6 grams of Betaine HCl.

Use only Anhydrous Betaine, frequently labelled as Trimethylglycine.

****************************************************************************************

> >> > _http://www.commonvoice.com/article.asp?colid=4270_> > (http://www.commonvoice.com/article.asp?colid=4270)> > Diet for Metabolic Syndrome> > Regina Wilshire> > March 1, 2006> >> > Metabolic Syndrome> > While doing a search last night for some information about one of the> > complications of Metabolic Syndrome, I stumbled upon an interesting> review in the> > World Journal of Gastroenterology - _Non-alcoholic fatty liver disease> and the> > metabolic syndrome: Effects of weightloss and a review of popular> diets.> > Are low carbohydrate diets the answer?_> > (http://www.wjgnet.com/1007-9327/12/345.asp)> > Researchers at the University of Connecticut Health Center, in> Farmington,> > Connecticut, reviewed the role of the metabolic syndrome, especially> insulin> > resistance and obesity in the development of non-alcoholic fatty liver> > disease (NAFLD), to investigate the effect of weight loss on NAFLD> and, finally, to> > evaluate popular diets and compare them with regard to their effects> on the> > metabolic syndrome and NAFLD.> > The above article is fairly long, but the researchers take things step> by> > step and review the degeneative processes that occur in metabolic> syndrome.> > They then look at the various therapies that have been evaluated,> "Therapies> > that have been evaluated include lifestyle changes such as diet and> exercise,> > antioxidants like vitamin E and betaine, cytoprotective agents such as> > ursodeoxycholic acid, lipid-lowering agents, anti-diabetics,> weight-loss agents like> > orlistat and iron reduction therapy, i.e. phlebotomy. The management> of> > associated conditions, such as diabetes, obesity and hyperlipidemia,> is> > especially important, given their association with more advanced liver> disease."> > The most common of these therapies is weight loss since it, by itself,> often> > leads to improvements in insulin sensitivity, cholesterol, blood> pressure and> > glycemic control - all problems associated with metabolic syndrome.> Their> > concern, however is that "Improvement in liver biochemistry and> > ultrasonographic appearance is a consistent finding with moderate> weight reduction.> > However, serum aminotransferases are unreliable markers for follow-up,> and do not> > provide accurate data on prognosis. Worsening of fibrosis can occur> even as> > the levels of transaminases decline. A few studies have evaluated and> shown> > histologic improvement."> > After a review of traditional weight loss recommendation studies, they> move> > to "popular diets."> > The effects of many popular diets on fatty liver are not known.> However,> > metabolic improvements related to dietary weight reduction may> favorably> > influence NASH. If dietary intervention can positively affect insulin> resistance and> > other features of the metabolic syndrome, it would be important to> know> > which particular diet is most beneficial.> > One of the most startling statements in the review "A diet high in> > carbohydrates results in an increase in blood glucose, insulin and> triglycerides, all> > of which are risk factors for the development of NAFLD."> > This was stated after a favorable look at studies that used> traditional> > dietary therapies!> > Most researchers are well aware of the dangers of low-fat carbohydrate> rich> > diets and I have to applaud these researchers for stating it here> simply -> > the literature is rich with data that clearly shows low-fat diets do> not result> > in significant improvements, but few will state it - it there in their> data,> > but they simply omit any questions or concerns with "unfavorable"> outcomes> > from low-fat diets.> > These researchers continue, "Carbohydrate restriction leads to ketosis> > resulting not only in weight loss, but also a decrease in blood> glucose, insulin> > and triglyceride levels. Studies have shown these diets to be> effective in> > short-term weight loss. Early weight loss is a result of diuresis> associated> > with ketone and urea nitrogen excretion. However, over time, weight> loss is a> > result of loss of body fat. Proponents believe that these diets have a> high> > satiety level, which make them easier to adhere to. This is very> important, as> > dietary adherence is one of the main challenges faced by dieters.> Questions> > with regard to their nutritional adequacy and long-term effects have> been> > raised. In the short-term, these diets have been found to be safe. "> > When reviewing studies that compared a low-fat diet to a low-carb> diet, it> > was found that "Effects on biochemical markers associated with the> metabolic> > syndrome appear to be more favorable with low-carbohydrate diets. In> general,> > these diets show greater improvements in insulin sensitivity,> triglyceride and> > high-density cholesterol levels. It is possible that for patients with> the> > metabolic syndrome, a low-carbohydrate diet may be more advantageous.> This, in> > turn, may positively affect NAFLD."> > In their conclusions - "Traditionally, a low-fat diet has been> recommended,> > but recent studies, show greater short-term weight loss and greater> > improvement in markers of the metabolic syndrome without significant> adverse effects> > with low-carbohydrate diets. This raises the question of whether> > low-carbohydrate diets should be recommended as part of a weight loss> strategy for our> > patients. At this point, questions regarding the nutritional adequacy> and> > long-term safety remain. While studies have evaluated the effect of> these diets on> > weight loss, cardiovascular and metabolic marker studies are needed to> > evaluate the effect of these diets specifically on NAFLD."> >> > Regards,> >> >> > Vergel> > powerusa dot org> >> >> > "The great tragedy of life is not that people set their sights too> high and> > fail to achieve their goals but they set their sights too low and do."> > Michelangelo> >>

[Guest guest]

u might try iherb.com under betaine

[Guest guest]

u might try iherb.com under betaine

[Guest guest]

u might try iherb.com under betaine

[Guest guest]

The iHerb offerings of Trimethylglycines are all more expensive by a

few dollars.

The products listed under Betaine are all Betaine HCl, which increases

stomach acid, not the same thing as Anhydrous Betaine.

>

> u might try iherb.com under betaine

>

[Guest guest]

The iHerb offerings of Trimethylglycines are all more expensive by a

few dollars.

The products listed under Betaine are all Betaine HCl, which increases

stomach acid, not the same thing as Anhydrous Betaine.

>

> u might try iherb.com under betaine

>

[Guest guest]

The iHerb offerings of Trimethylglycines are all more expensive by a

few dollars.

The products listed under Betaine are all Betaine HCl, which increases

stomach acid, not the same thing as Anhydrous Betaine.

>

> u might try iherb.com under betaine

>